alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid has been researched along with Disease Models, Animal in 112 studies
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Considerable evidence has demonstrated that alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor blockade has an antinociceptive effect on inflammatory pain." | 7.73 | New role for spinal Stargazin in alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-mediated pain sensitization after inflammation. ( Johns, RA; Skinner, J; Su, Q; Tao, F, 2006) |
| " Previously, we showed that α-tocopherol (α-T) reduces hippocampal neuroglial activation and neurodegeneration in the rat model of kainic acid (KA)-induced status epilepticus (SE)." | 3.88 | Neurobiological Correlates of Alpha-Tocopherol Antiepileptogenic Effects and MicroRNA Expression Modulation in a Rat Model of Kainate-Induced Seizures. ( Albertini, MC; Ambrogini, P; Bartolini, D; Betti, M; Cuppini, R; Di Palma, M; Galati, C; Galli, F; Lattanzi, D; Minelli, A; Olivieri, F; Palma, E; Ruffolo, G; Saccomanno, S; Savelli, D; Torquato, P, 2018) |
| " Whereas MTA reduced the neuronal cell death in pilocarpine-induced status epilepticus and the size of the lesion in global but not focal ischemic brain damage, it was ineffective in preserving dopaminergic neurons of the substantia nigra in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)-mice model." | 3.80 | Differential neuroprotective effects of 5'-deoxy-5'-methylthioadenosine. ( Alberch, J; Ceña, V; Collon, KW; Domercq, M; Fernández-Díez, B; Franco, R; Giralt, A; Giralt, E; Gottlieb, M; Lopez, I; Martínez-Pinilla, E; Matute, C; Moreno, B; Parent, JM; Posadas, I; Sánchez-Gómez, MV; Teixido, M; Villoslada, P; Zhang, H, 2014) |
| "Novel N3 aryl/heteroaryl substituted 2-((benzyloxy and phenylthio) methyl) 6,7-dimethoxyquinazolin-4(3H)- ones (8a-8l) were synthesized and evaluated for their anticonvulsant activity using various models of epilepsy, such as maximal electroshock (MES), subcutaneous pentylenetetrazole (scPTZ) and intracerebroventricular AMPA (α-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid)-induced seizures in mice." | 3.80 | Design, synthesis and pharmacological evaluation of N3 aryl/ heteroaryl substituted 2-((benzyloxy and phenylthio) methyl) 6,7- dimethoxyquinazolin-4(3H)-ones as potential anticonvulsant agents. ( Banerjee, AG; Das, N; Shrivastava, SK, 2014) |
| "In this study, we tested whether AMPA alone has an antidepressant effect and if the combination of AMPA and ketamine provides added benefit in Wistar-Kyoto rats, a putative animal model of depression." | 3.79 | Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. ( Akinfiresoye, L; Tizabi, Y, 2013) |
| "Mutations in the hypoxia-inducible factor angiogenin (ANG) have been identified in Amyotrophic Lateral Sclerosis (ALS) patients, but the potential role of ANG in ALS pathogenesis was undetermined." | 3.74 | Control of motoneuron survival by angiogenin. ( Concannon, CG; Connaughton, D; Fenner, B; Greenway, MJ; Hardiman, O; Kieran, D; King, MA; Prehn, JH; Sebastia, J, 2008) |
| " After having established the mouse model of analgesia by intraperitoneal or subcutaneous injections of appropriate doses of emulsified enflurane, isoflurane or sevoflurane, we injected different doses of AMPA intrathecally and observed effects on the pain threshold using the hot-plate and acetic acid-induced writhing tests." | 3.74 | Spinal alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors may mediate the analgesic effects of emulsified halogenated anaesthetics. ( Dai, TJ; Hang, LH; Shao, DH; Yang, YH; Zeng, YM, 2007) |
| "Considerable evidence has demonstrated that alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor blockade has an antinociceptive effect on inflammatory pain." | 3.73 | New role for spinal Stargazin in alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-mediated pain sensitization after inflammation. ( Johns, RA; Skinner, J; Su, Q; Tao, F, 2006) |
| "The anticonvulsant activity of felbamate against sound-induced seizures was studied in the DBA/2 mouse model." | 3.69 | Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. ( Aguglia, U; Bertorelli, R; De Sarro, A; De Sarro, G; Ongini, E, 1994) |
| " GYKI 52466 was also protective against seizures and lethality induced by 4-aminopyridine, kainate and AMPA, but not by NMDA, whereas NBQX was ineffective in these chemoconvulsant tests." | 3.68 | Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. ( Donevan, SD; Rogawski, MA; Yamaguchi, S, 1993) |
| " Most frequently reported adverse events were nausea, dizziness, and headache." | 2.77 | A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder. ( Adler, LA; Cazorla, P; Kroon, RA; Schipper, J; Shahid, M; Stein, M; Szegedi, A; Tarazi, FI, 2012) |
| "Neurolathyrism, konzo, and amyotrophic lateral sclerosis-parkinsonism-dementia complex (ALS-PDC) have attracted researchers to study the pathology of motor neuron (MN) diseases such as ALS." | 2.61 | [Research in Motor Neuron Diseases Caused by Natural Substances: Focus on Pathological Mechanisms of Neurolathyrism]. ( Kusama-Eguchi, K, 2019) |
| "Key pathological features of Alzheimer's disease (AD) include build-up of amyloid β (Aβ), which promotes synaptic abnormalities and ultimately leads to neuronal cell death." | 1.91 | Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration. ( Ainge, JA; Doherty, G; Duncan, S; Flewitt, I; Hamilton, K; Harvey, J; Holiday, A; MacLeod, B; Malekizadeh, Y; Manolescu, C, 2023) |
| "As a neurodegenerative disease, Alzheimer's disease (AD) seriously affects the health of older people." | 1.72 | A Class I HDAC Inhibitor Rescues Synaptic Damage and Neuron Loss in APP-Transfected Cells and APP/PS1 Mice through the GRIP1/AMPA Pathway. ( Chen, J; Chen, L; Chu, H; Guo, Y; Han, Y; Liu, J; Ma, H; Wang, C; Yu, X; Zhang, C, 2022) |
| "However, the impact of ZDHHC8 on seizures remains unclear." | 1.48 | ZDHHC8 critically regulates seizure susceptibility in epilepsy. ( Chen, G; Gao, X; He, M; Hu, Y; Li, Y; Ma, Y; Tian, X; Wang, Q; Wang, W; Wang, X; Xu, D; Yang, Q; Yang, Y; Zheng, F; Zhou, R, 2018) |
| "Because motoneuron degeneration is the main pathological hallmark in motoneuron diseases, and excitotoxicity is an important mechanism of neuronal death in this type of disorders, in this work we tested whether the tetanus toxin C-fragment is able to protect MN in the spinal cord in vivo." | 1.48 | Tetanus toxin C-fragment protects against excitotoxic spinal motoneuron degeneration in vivo. ( Netzahualcoyotzi, C; Tapia, R, 2018) |
| "In 2-month-old mice, no β-amyloid plaques deposition, but the presence of soluble oligomers, were found in CA1 area but not in dentate gyrus (DG)." | 1.42 | Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. ( Borsello, T; Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Ghiglieri, V; Sclip, A; Tantucci, M; Tozzi, A, 2015) |
| "Hypoglycemia is a common adverse event and can injure central nervous system (CNS) white matter (WM)." | 1.40 | Novel hypoglycemic injury mechanism: N-methyl-D-aspartate receptor-mediated white matter damage. ( Brown, AM; Chen, S; Evans, RD; Hamner, MA; Ransom, BR; Yang, X; Ye, ZC, 2014) |
| " For this purpose we conducted a dose-response study at concentrations of AMPA between 0." | 1.35 | Pattern of injury with a graded excitotoxic insult and ensuing chronic medial septal damage in the rat brain. ( Andrés, N; Batlle, M; Mahy, N; Malpesa, Y; Prats, A; Pugliese, M; Rodríguez, MJ, 2009) |
| "Secondary mechanical allodynia resulting from a thermal stimulus (52." | 1.33 | Activated PKA and PKC, but not CaMKIIalpha, are required for AMPA/Kainate-mediated pain behavior in the thermal stimulus model. ( Jones, TL; Sorkin, LS, 2005) |
| "Increased seizure duration [3,522 +/- 660 sec (SEM) vs." | 1.33 | Neurodegenerative actions of interleukin-1 in the rat brain are mediated through increases in seizure activity. ( Allan, SM; Davies, RE; Heenan, LE; Patel, HC; Ross, FM; Rothwell, NJ, 2006) |
| "Cognitive decline in Alzheimer's disease (AD) stems from the progressive dysfunction of synaptic connections within cortical neuronal microcircuits." | 1.33 | Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. ( Burnashev, N; Farkas, T; Fülöp, L; Harkany, T; Härtig, W; Holmgren, C; Min, R; Penke, B; Shemer, I; Sousa, KM; Tanila, H; Zilberter, M; Zilberter, Y, 2006) |
| "Chronic relapsing/remitting experimental autoimmune encephalomyelitis (EAE) can be induced in 8-week-old female SJL/J(H-2) mice via inoculation with the p139-151 peptide of myelin proteolipid protein (PLP), Mycobacterium tuberculosis (MT), complete Freund's adjuvant (CFA), and Bordatella pertussis." | 1.32 | An electrophysiological model of spinal transmission deficits in mouse experimental autoimmune encephalomyelitis. ( Black, MD; Hanak, SE; McMonagle-Strucko, K; Pulicicchio, C; Reilly, EM; Wettstein, JG; Wotanis, J; Zhu, B, 2004) |
| "Thermal hyperalgesia requires NMDA receptor activation and is primarily mediated by production of nitric oxide." | 1.29 | Spinal mediators of hyperalgesia. ( Gebhart, GF; Meller, ST, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (12.50) | 18.2507 |
| 2000's | 37 (33.04) | 29.6817 |
| 2010's | 54 (48.21) | 24.3611 |
| 2020's | 7 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Han, Y | 1 |
| Chen, L | 1 |
| Liu, J | 1 |
| Chen, J | 1 |
| Wang, C | 1 |
| Guo, Y | 1 |
| Yu, X | 1 |
| Zhang, C | 1 |
| Chu, H | 1 |
| Ma, H | 1 |
| Mishra, A | 1 |
| Singla, R | 1 |
| Kumar, R | 1 |
| Sharma, A | 1 |
| Joshi, R | 1 |
| Sarma, P | 1 |
| Kaur, G | 1 |
| Prajapat, M | 1 |
| Bhatia, A | 1 |
| Medhi, B | 1 |
| Doherty, G | 3 |
| Holiday, A | 3 |
| Malekizadeh, Y | 3 |
| Manolescu, C | 3 |
| Duncan, S | 3 |
| Flewitt, I | 3 |
| Hamilton, K | 3 |
| MacLeod, B | 3 |
| Ainge, JA | 3 |
| Harvey, J | 3 |
| Habib, MZ | 1 |
| Elnahas, EM | 1 |
| Aboul-Ela, YM | 1 |
| Ebeid, MA | 1 |
| Tarek, M | 1 |
| Sadek, DR | 1 |
| Negm, EA | 1 |
| Abdelhakam, DA | 1 |
| Aboul-Fotouh, S | 1 |
| Abghari, M | 1 |
| Vu, JTCM | 1 |
| Eckberg, N | 1 |
| Aldana, BI | 1 |
| Kohlmeier, KA | 1 |
| Colín, E | 1 |
| Ramírez-Jarquín, UN | 2 |
| Tapia, R | 8 |
| Fernández-Pérez, EJ | 1 |
| Gallegos, S | 1 |
| Armijo-Weingart, L | 1 |
| Araya, A | 1 |
| Riffo-Lepe, NO | 1 |
| Cayuman, F | 1 |
| Aguayo, LG | 1 |
| Li, MX | 1 |
| Zheng, HL | 1 |
| Luo, Y | 1 |
| He, JG | 1 |
| Wang, W | 2 |
| Han, J | 1 |
| Zhang, L | 1 |
| Wang, X | 2 |
| Ni, L | 1 |
| Zhou, HY | 1 |
| Hu, ZL | 1 |
| Wu, PF | 1 |
| Jin, Y | 1 |
| Long, LH | 1 |
| Zhang, H | 2 |
| Hu, G | 1 |
| Chen, JG | 1 |
| Wang, F | 1 |
| Gulchina, Y | 1 |
| Xu, SJ | 1 |
| Snyder, MA | 1 |
| Elefant, F | 1 |
| Gao, WJ | 1 |
| Bretin, S | 1 |
| Krazem, A | 1 |
| Henkous, N | 1 |
| Froger-Colleaux, C | 1 |
| Mocaer, E | 1 |
| Louis, C | 1 |
| Perdaems, N | 1 |
| Marighetto, A | 1 |
| Beracochea, D | 1 |
| Ambrogini, P | 1 |
| Albertini, MC | 1 |
| Betti, M | 1 |
| Galati, C | 1 |
| Lattanzi, D | 1 |
| Savelli, D | 1 |
| Di Palma, M | 1 |
| Saccomanno, S | 1 |
| Bartolini, D | 1 |
| Torquato, P | 1 |
| Ruffolo, G | 1 |
| Olivieri, F | 1 |
| Galli, F | 1 |
| Palma, E | 1 |
| Minelli, A | 1 |
| Cuppini, R | 1 |
| Hettinger, JC | 1 |
| Lee, H | 1 |
| Bu, G | 1 |
| Holtzman, DM | 1 |
| Cirrito, JR | 1 |
| Baglietto-Vargas, D | 1 |
| Prieto, GA | 1 |
| Limon, A | 1 |
| Forner, S | 1 |
| Rodriguez-Ortiz, CJ | 1 |
| Ikemura, K | 1 |
| Ager, RR | 1 |
| Medeiros, R | 1 |
| Trujillo-Estrada, L | 1 |
| Martini, AC | 1 |
| Kitazawa, M | 1 |
| Davila, JC | 1 |
| Cotman, CW | 1 |
| Gutierrez, A | 1 |
| LaFerla, FM | 1 |
| Yang, Q | 1 |
| Zheng, F | 1 |
| Hu, Y | 1 |
| Yang, Y | 2 |
| Li, Y | 1 |
| Chen, G | 1 |
| He, M | 1 |
| Zhou, R | 1 |
| Ma, Y | 1 |
| Xu, D | 1 |
| Tian, X | 1 |
| Gao, X | 1 |
| Wang, Q | 1 |
| Ariffin, MZ | 1 |
| Ibrahim, KM | 1 |
| Lee, AT | 1 |
| Lee, RZ | 1 |
| Poon, SY | 1 |
| Thong, HK | 1 |
| Liu, EHC | 1 |
| Low, CM | 1 |
| Khanna, S | 1 |
| Papathanou, M | 1 |
| Creed, M | 1 |
| Dorst, MC | 1 |
| Bimpisidis, Z | 1 |
| Dumas, S | 1 |
| Pettersson, H | 1 |
| Bellone, C | 1 |
| Silberberg, G | 1 |
| Lüscher, C | 2 |
| Wallén-Mackenzie, Å | 1 |
| Netzahualcoyotzi, C | 2 |
| Kusama-Eguchi, K | 1 |
| Amini, M | 1 |
| Ma, CL | 1 |
| Farazifard, R | 1 |
| Zhu, G | 1 |
| Zhang, Y | 1 |
| Vanderluit, J | 1 |
| Zoltewicz, JS | 1 |
| Hage, F | 1 |
| Savitt, JM | 1 |
| Lagace, DC | 1 |
| Slack, RS | 1 |
| Beique, JC | 1 |
| Baudry, M | 1 |
| Greer, PA | 1 |
| Bergeron, R | 1 |
| Park, DS | 1 |
| Soman, S | 1 |
| Anju, TR | 1 |
| Jayanarayanan, S | 1 |
| Antony, S | 1 |
| Paulose, CS | 1 |
| Akinfiresoye, L | 1 |
| Tizabi, Y | 1 |
| Morice, E | 1 |
| Farley, S | 1 |
| Poirier, R | 1 |
| Dallerac, G | 1 |
| Chagneau, C | 1 |
| Pannetier, S | 1 |
| Hanauer, A | 1 |
| Davis, S | 1 |
| Vaillend, C | 1 |
| Laroche, S | 1 |
| Malik, S | 1 |
| Bahare, RS | 1 |
| Khan, SA | 1 |
| Yang, X | 1 |
| Hamner, MA | 1 |
| Brown, AM | 1 |
| Evans, RD | 1 |
| Ye, ZC | 1 |
| Chen, S | 1 |
| Ransom, BR | 1 |
| Santa-Cruz, LD | 2 |
| Moreno, B | 1 |
| Lopez, I | 1 |
| Fernández-Díez, B | 1 |
| Gottlieb, M | 1 |
| Matute, C | 2 |
| Sánchez-Gómez, MV | 1 |
| Domercq, M | 1 |
| Giralt, A | 1 |
| Alberch, J | 1 |
| Collon, KW | 1 |
| Parent, JM | 1 |
| Teixido, M | 1 |
| Giralt, E | 1 |
| Ceña, V | 1 |
| Posadas, I | 1 |
| Martínez-Pinilla, E | 1 |
| Villoslada, P | 1 |
| Franco, R | 1 |
| Das, N | 1 |
| Banerjee, AG | 1 |
| Shrivastava, SK | 1 |
| Kolodziejczyk, K | 1 |
| Parsons, MP | 1 |
| Southwell, AL | 1 |
| Hayden, MR | 2 |
| Raymond, LA | 1 |
| Gong, K | 1 |
| Kung, LH | 1 |
| Magni, G | 1 |
| Bhargava, A | 1 |
| Jasmin, L | 1 |
| Guo, Z | 1 |
| Cao, G | 1 |
| Yang, H | 1 |
| Zhou, H | 1 |
| Li, L | 2 |
| Cao, Z | 1 |
| Yu, B | 1 |
| Kou, J | 1 |
| Pascoli, V | 1 |
| Terrier, J | 1 |
| Espallergues, J | 1 |
| Valjent, E | 1 |
| O'Connor, EC | 1 |
| Morelli, E | 1 |
| Ghiglieri, V | 2 |
| Pendolino, V | 1 |
| Bagetta, V | 1 |
| Pignataro, A | 1 |
| Fejtova, A | 1 |
| Costa, C | 2 |
| Ammassari-Teule, M | 1 |
| Gundelfinger, ED | 1 |
| Picconi, B | 1 |
| Calabresi, P | 2 |
| Pochwat, B | 1 |
| Sowa-Kucma, M | 1 |
| Kotarska, K | 1 |
| Misztak, P | 1 |
| Nowak, G | 1 |
| Szewczyk, B | 1 |
| Tozzi, A | 1 |
| Sclip, A | 1 |
| Tantucci, M | 1 |
| de Iure, A | 1 |
| Di Filippo, M | 1 |
| Borsello, T | 1 |
| Williams, K | 1 |
| Balsor, JL | 1 |
| Beshara, S | 1 |
| Beston, BR | 1 |
| Jones, DG | 1 |
| Murphy, KM | 1 |
| Cabrera-Pastor, A | 1 |
| Taoro, L | 1 |
| Llansola, M | 1 |
| Felipo, V | 1 |
| Parker, PR | 1 |
| Lalive, AL | 1 |
| Kreitzer, AC | 1 |
| Guerrero-Castillo, S | 1 |
| Uribe-Carvajal, S | 1 |
| Zhang, TT | 1 |
| Shen, FY | 1 |
| Ma, LQ | 1 |
| Wen, W | 1 |
| Wang, B | 1 |
| Peng, YZ | 1 |
| Wang, ZR | 1 |
| Zhao, X | 1 |
| Borralleras, C | 1 |
| Mato, S | 1 |
| Amédée, T | 1 |
| Mulle, C | 2 |
| Pérez-Jurado, LA | 1 |
| Campuzano, V | 1 |
| Russo, E | 2 |
| Citraro, R | 1 |
| De Fazio, S | 1 |
| Marra, R | 1 |
| Gitto, R | 2 |
| Chimirri, A | 2 |
| De Sarro, G | 3 |
| Di Paola, ED | 1 |
| Hang, L | 1 |
| Shao, D | 1 |
| Sun, W | 1 |
| Dai, T | 1 |
| Zeng, Y | 1 |
| Ricceri, L | 1 |
| De Filippis, B | 1 |
| Laviola, G | 1 |
| Yan, B | 1 |
| Harden, SW | 1 |
| Gozal, D | 1 |
| Lin, Y | 1 |
| Wead, WB | 1 |
| Wurster, RD | 1 |
| Cheng, ZJ | 1 |
| Kieran, D | 2 |
| Sebastia, J | 1 |
| Greenway, MJ | 1 |
| King, MA | 1 |
| Connaughton, D | 1 |
| Concannon, CG | 1 |
| Fenner, B | 1 |
| Hardiman, O | 1 |
| Prehn, JH | 1 |
| Kiagiadaki, F | 1 |
| Savvaki, M | 1 |
| Thermos, K | 1 |
| Rodríguez, MJ | 1 |
| Prats, A | 1 |
| Malpesa, Y | 1 |
| Andrés, N | 1 |
| Pugliese, M | 1 |
| Batlle, M | 1 |
| Mahy, N | 1 |
| Dong, XD | 1 |
| Svensson, P | 1 |
| Cairns, BE | 1 |
| Loría, F | 1 |
| Petrosino, S | 1 |
| Hernangómez, M | 1 |
| Mestre, L | 1 |
| Spagnolo, A | 1 |
| Correa, F | 1 |
| Di Marzo, V | 1 |
| Docagne, F | 1 |
| Guaza, C | 1 |
| Pitt, D | 1 |
| Gonzales, E | 1 |
| Cross, AH | 1 |
| Goldberg, MP | 1 |
| Ortiz, AN | 1 |
| Kurth, BJ | 1 |
| Osterhaus, GL | 1 |
| Johnson, MA | 1 |
| Roberts, BM | 1 |
| Holden, DE | 1 |
| Shaffer, CL | 1 |
| Seymour, PA | 1 |
| Menniti, FS | 1 |
| Schmidt, CJ | 1 |
| Williams, GV | 1 |
| Castner, SA | 1 |
| Silberman, Y | 1 |
| Ariwodola, OJ | 1 |
| Chappell, AM | 1 |
| Yorgason, JT | 1 |
| Weiner, JL | 1 |
| Sawant, PM | 1 |
| Tyndall, JD | 1 |
| Holland, PT | 1 |
| Peake, BM | 1 |
| Mountfort, DO | 1 |
| Kerr, DS | 1 |
| Tovar-Y-Romo, LB | 2 |
| Zhang, YH | 1 |
| Wang, XM | 1 |
| Ennis, M | 1 |
| Simmons, DA | 1 |
| Mehta, RA | 1 |
| Lauterborn, JC | 1 |
| Gall, CM | 1 |
| Lynch, G | 1 |
| Huneau, C | 1 |
| Demont-Guignard, S | 1 |
| Benquet, P | 1 |
| Martin, B | 1 |
| Wendling, F | 1 |
| Kopach, O | 1 |
| Kao, SC | 1 |
| Petralia, RS | 1 |
| Belan, P | 1 |
| Tao, YX | 1 |
| Voitenko, N | 1 |
| Li, J | 1 |
| Baccei, ML | 1 |
| Damont, A | 1 |
| Boisgard, R | 1 |
| Kuhnast, B | 1 |
| Lemée, F | 1 |
| Raggiri, G | 1 |
| Scarf, AM | 1 |
| Da Pozzo, E | 1 |
| Selleri, S | 1 |
| Martini, C | 1 |
| Tavitian, B | 1 |
| Kassiou, M | 1 |
| Dollé, F | 1 |
| Weiss, HR | 1 |
| Liu, X | 1 |
| Grewal, P | 1 |
| Chi, OZ | 1 |
| Adler, LA | 1 |
| Kroon, RA | 1 |
| Stein, M | 1 |
| Shahid, M | 1 |
| Tarazi, FI | 1 |
| Szegedi, A | 1 |
| Schipper, J | 1 |
| Cazorla, P | 1 |
| Lanore, F | 1 |
| Labrousse, VF | 1 |
| Szabo, Z | 1 |
| Normand, E | 1 |
| Blanchet, C | 1 |
| Nobrega, JN | 1 |
| Raymond, R | 1 |
| Barlow, K | 1 |
| Hamann, M | 1 |
| Richter, A | 1 |
| Murray, TK | 1 |
| Whalley, K | 1 |
| Robinson, CS | 1 |
| Ward, MA | 1 |
| Hicks, CA | 1 |
| Lodge, D | 2 |
| Vandergriff, JL | 1 |
| Baumbarger, P | 1 |
| Siuda, E | 1 |
| Gates, M | 1 |
| Ogden, AM | 2 |
| Skolnick, P | 1 |
| Zimmerman, DM | 1 |
| Nisenbaum, ES | 1 |
| Bleakman, D | 2 |
| O'Neill, MJ | 1 |
| Orlando, V | 1 |
| Quartarone, S | 1 |
| De Sarro, A | 2 |
| Ferreri, G | 1 |
| Hanak, SE | 1 |
| Reilly, EM | 1 |
| Wotanis, J | 1 |
| Zhu, B | 1 |
| Pulicicchio, C | 1 |
| McMonagle-Strucko, K | 1 |
| Wettstein, JG | 1 |
| Black, MD | 1 |
| Jones, TL | 2 |
| Sorkin, LS | 2 |
| Greensmith, L | 1 |
| Saura, CA | 1 |
| Choi, SY | 1 |
| Beglopoulos, V | 1 |
| Malkani, S | 1 |
| Zhang, D | 1 |
| Shankaranarayana Rao, BS | 1 |
| Chattarji, S | 1 |
| Kelleher, RJ | 1 |
| Kandel, ER | 1 |
| Duff, K | 1 |
| Kirkwood, A | 1 |
| Shen, J | 1 |
| Hossain, MA | 1 |
| Russell, JC | 1 |
| O'Brien, R | 1 |
| Laterra, J | 1 |
| Shimogori, H | 1 |
| Yamashita, H | 1 |
| Dominguez, E | 1 |
| Iyengar, S | 1 |
| Shannon, HE | 1 |
| Alt, A | 1 |
| Arnold, BM | 1 |
| Bell, MG | 1 |
| Bleisch, TJ | 1 |
| Buckmaster, JL | 1 |
| Castano, AM | 1 |
| Del Prado, M | 1 |
| Escribano, A | 1 |
| Filla, SA | 1 |
| Ho, KH | 1 |
| Hudziak, KJ | 1 |
| Jones, CK | 1 |
| Martinez-Perez, JA | 1 |
| Mateo, A | 1 |
| Mathes, BM | 1 |
| Mattiuz, EL | 1 |
| Simmons, RM | 1 |
| Stack, DR | 1 |
| Stratford, RE | 1 |
| Winter, MA | 1 |
| Wu, Z | 1 |
| Ornstein, PL | 1 |
| Epsztein, J | 1 |
| Represa, A | 1 |
| Jorquera, I | 1 |
| Ben-Ari, Y | 1 |
| Crépel, V | 1 |
| Yoon, MH | 1 |
| Bae, HB | 1 |
| Choi, JI | 1 |
| Jeong, SW | 1 |
| Chung, SS | 1 |
| Yoo, KY | 1 |
| Jeong, CY | 1 |
| Kim, SJ | 1 |
| Chung, ST | 1 |
| Kim, CM | 1 |
| An, TH | 1 |
| Sharif Naeini, R | 1 |
| Cahill, CM | 1 |
| Ribeiro-da-Silva, A | 1 |
| Ménard, HA | 1 |
| Henry, JL | 1 |
| Patel, HC | 1 |
| Ross, FM | 1 |
| Heenan, LE | 1 |
| Davies, RE | 1 |
| Rothwell, NJ | 1 |
| Allan, SM | 1 |
| André, VM | 1 |
| Cepeda, C | 2 |
| Venegas, A | 1 |
| Gomez, Y | 1 |
| Levine, MS | 2 |
| van de Bovenkamp-Janssen, MC | 1 |
| van der Kloet, JC | 1 |
| van Luijtelaar, G | 1 |
| Roubos, EW | 1 |
| Shemer, I | 1 |
| Holmgren, C | 1 |
| Min, R | 1 |
| Fülöp, L | 1 |
| Zilberter, M | 1 |
| Sousa, KM | 1 |
| Farkas, T | 1 |
| Härtig, W | 1 |
| Penke, B | 1 |
| Burnashev, N | 1 |
| Tanila, H | 1 |
| Zilberter, Y | 1 |
| Harkany, T | 1 |
| Tao, F | 1 |
| Skinner, J | 1 |
| Su, Q | 1 |
| Johns, RA | 1 |
| Lai, C | 1 |
| Xie, C | 1 |
| McCormack, SG | 1 |
| Chiang, HC | 1 |
| Michalak, MK | 1 |
| Lin, X | 1 |
| Chandran, J | 1 |
| Shim, H | 1 |
| Shimoji, M | 1 |
| Cookson, MR | 1 |
| Huganir, RL | 1 |
| Rothstein, JD | 1 |
| Price, DL | 1 |
| Wong, PC | 1 |
| Martin, LJ | 1 |
| Zhu, JJ | 1 |
| Cai, H | 1 |
| Tseng, KY | 1 |
| Lewis, BL | 1 |
| Lipska, BK | 1 |
| O'Donnell, P | 1 |
| Gigler, G | 1 |
| Móricz, K | 1 |
| Agoston, M | 1 |
| Simó, A | 1 |
| Albert, M | 1 |
| Benedek, A | 1 |
| Kapus, G | 2 |
| Kertész, S | 1 |
| Vegh, M | 1 |
| Barkóczy, J | 1 |
| Markó, B | 1 |
| Szabó, G | 1 |
| Matucz, E | 1 |
| Gacsályi, I | 1 |
| Lévay, G | 1 |
| Hársing, LG | 2 |
| Szénási, G | 1 |
| Hang, LH | 1 |
| Shao, DH | 1 |
| Yang, YH | 1 |
| Dai, TJ | 1 |
| Zeng, YM | 1 |
| Lee, CY | 1 |
| Fu, WM | 1 |
| Chen, CC | 1 |
| Su, MJ | 1 |
| Liou, HH | 1 |
| Chen, Q | 1 |
| Harris, C | 1 |
| Brown, CS | 1 |
| Howe, A | 1 |
| Surmeier, DJ | 1 |
| Reiner, A | 1 |
| Muir, JL | 1 |
| Page, KJ | 1 |
| Sirinathsinghji, DJ | 1 |
| Robbins, TW | 1 |
| Everitt, BJ | 1 |
| Meller, ST | 1 |
| Gebhart, GF | 1 |
| Ongini, E | 1 |
| Bertorelli, R | 1 |
| Aguglia, U | 1 |
| Ossowska, K | 1 |
| Puel, JL | 1 |
| Saffiedine, S | 1 |
| Gervais d'Aldin, C | 1 |
| Eybalin, M | 1 |
| Pujol, R | 1 |
| LeBlanc, MH | 1 |
| Li, XQ | 1 |
| Huang, M | 1 |
| Patel, DM | 1 |
| Smith, EE | 1 |
| Yamaguchi, S | 1 |
| Donevan, SD | 1 |
| Rogawski, MA | 1 |
| Gill, R | 1 |
| Potschka, H | 1 |
| Löscher, W | 1 |
| Wlaź, P | 1 |
| Behl, B | 1 |
| Hofmann, HP | 1 |
| Treiber, HJ | 1 |
| Szabo, L | 1 |
| Auberson, YP | 1 |
| Acklin, P | 1 |
| Bischoff, S | 1 |
| Moretti, R | 1 |
| Ofner, S | 1 |
| Schmutz, M | 1 |
| Veenstra, SJ | 1 |
| Sinor, AD | 1 |
| Greenberg, DA | 1 |
| Abrahám, G | 1 |
| Sólyom, S | 1 |
| Csuzdi, E | 1 |
| Berzsenyi, P | 1 |
| Ling, I | 1 |
| Tarnawa, I | 1 |
| Hámori, T | 1 |
| Pallagi, I | 1 |
| Horváth, K | 1 |
| Andrási, F | 1 |
| Király, I | 1 |
| Patthy, M | 1 |
| Horváth, G | 1 |
| Chizh, BA | 1 |
| Schlütz, H | 1 |
| Scheede, M | 1 |
| Englberger, W | 1 |
| Pratt, J | 2 |
| Jimonet, P | 2 |
| Bohme, GA | 2 |
| Boireau, A | 2 |
| Damour, D | 2 |
| Debono, MW | 2 |
| Genevois-Borella, A | 2 |
| Randle, JC | 2 |
| Ribeill, Y | 2 |
| Stutzmann, JM | 2 |
| Vuilhorgne, M | 2 |
| Mignani, S | 2 |
| Bouquerel, J | 1 |
| Hardy, JC | 1 |
| Hubert, P | 1 |
| Manfré, F | 1 |
| Nemecek, P | 1 |
| Ariano, MA | 1 |
| Calvert, CR | 1 |
| Flores-Hernández, J | 1 |
| Chandler, SH | 1 |
| Leavitt, BR | 1 |
| Cotton, P | 1 |
| Beal, MF | 1 |
| Ferrante, RJ | 1 |
| Swartz, KJ | 1 |
| Kowall, NW | 1 |
| Löschmann, PA | 1 |
| Lange, KW | 1 |
| Kunow, M | 1 |
| Rettig, KJ | 1 |
| Jähnig, P | 1 |
| Honoré, T | 1 |
| Turski, L | 1 |
| Wachtel, H | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776] | Phase 4 | 88 participants (Anticipated) | Interventional | 2018-04-03 | Enrolling by invitation | ||
| Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease[NCT02783430] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-08 | Recruiting | ||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| NMDA-Receptor Blockade in Huntington's Chorea[NCT00001930] | Phase 2 | 25 participants | Interventional | 1999-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
5 reviews available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Disease Models, Animal
| Article | Year |
|---|---|
[Research in Motor Neuron Diseases Caused by Natural Substances: Focus on Pathological Mechanisms of Neurolathyrism].
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; beta-Alanine; Cell Death; Disease | 2019 |
Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Brain; Desipramine; Disease Model | 2008 |
Excitotoxic lesions of basal forebrain cholinergic neurons: effects on learning, memory and attention.
Topics: Acetylcholine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; | 1993 |
The role of excitatory amino acids in experimental models of Parkinson's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Catalepsy; Disease M | 1994 |
Pharmacology of AMPA antagonists and their role in neuroprotection.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Disease Models, Animal; Excitator | 1997 |
1 trial available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Disease Models, Animal
| Article | Year |
|---|---|
A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder.
Topics: Adult; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Attention; Attention Defic | 2012 |
106 other studies available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
A Class I HDAC Inhibitor Rescues Synaptic Damage and Neuron Loss in APP-Transfected Cells and APP/PS1 Mice through the GRIP1/AMPA Pathway.
Topics: Adaptor Proteins, Signal Transducing; Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 2022 |
Granulocyte Colony-Stimulating Factor Improved Core Symptoms of Autism Spectrum Disorder via Modulating Glutamatergic Receptors in the Prefrontal Cortex and Hippocampus of Rat Brains.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autism Spectrum Disorder; Brain; | 2022 |
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2023 |
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2023 |
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2023 |
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2023 |
Risperidone impedes glutamate excitotoxicity in a valproic acid rat model of autism: Role of ADAR2 in AMPA GluA2 RNA editing.
Topics: Adenosine Deaminase; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autism Spect | 2023 |
Decanoic Acid Rescues Differences in AMPA-Mediated Calcium Rises in Hippocampal CA1 Astrocytes and Neurons in the 5xFAD Mouse Model of Alzheimer's Disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2023 |
Early motor deficits in the phalangeal fine movements induced by chronic AMPA infusion in the rat spinal cord assessed by a novel method: Phalangeal tension recording test.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Disease Models, Animal; Hand Stre | 2020 |
Changes in neuronal excitability and synaptic transmission in nucleus accumbens in a transgenic Alzheimer's disease mouse model.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Biomarkers; Di | 2020 |
Gene deficiency and pharmacological inhibition of caspase-1 confers resilience to chronic social defeat stress via regulating the stability of surface AMPARs.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anxiety; Behavior, Animal; Caspas | 2018 |
Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in the MAM model for schizophrenia.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Animals, Newborn; Cognition Disor | 2017 |
Synergistic enhancing-memory effect of donepezil and S 47445, an AMPA positive allosteric modulator, in middle-aged and aged mice.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Benzoxazines; | 2018 |
Neurobiological Correlates of Alpha-Tocopherol Antiepileptogenic Effects and MicroRNA Expression Modulation in a Rat Model of Kainate-Induced Seizures.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; alpha-Tocopherol; Animals; Blood-Brain Bar | 2018 |
AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2018 |
Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Cytoskeleton; | 2018 |
ZDHHC8 critically regulates seizure susceptibility in epilepsy.
Topics: Acyltransferases; Adolescent; Adult; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Anima | 2018 |
Forebrain medial septum sustains experimental neuropathic pain.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Disease Models, Animal; Glutamic | 2018 |
Targeting VGLUT2 in Mature Dopamine Neurons Decreases Mesoaccumbal Glutamatergic Transmission and Identifies a Role for Glutamate Co-release in Synaptic Plasticity by Increasing Baseline AMPA/NMDA Ratio.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Behavior, Animal; Co | 2018 |
Tetanus toxin C-fragment protects against excitotoxic spinal motoneuron degeneration in vivo.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Disease Models, Animal; Injection | 2018 |
Conditional disruption of calpain in the CNS alters dendrite morphology, impairs LTP, and promotes neuronal survival following injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazol | 2013 |
Impaired motor learning attributed to altered AMPA receptor function in the cerebellum of rats with temporal lobe epilepsy: ameliorating effects of Withania somnifera and withanolide A.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Carbamazepine; C | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Defective synaptic transmission and structure in the dentate gyrus and selective fear memory impairment in the Rsk2 mutant mouse model of Coffin-Lowry syndrome.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Coffin-Lowry Syndrome; Conditioni | 2013 |
Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Disease Models, | 2013 |
Novel hypoglycemic injury mechanism: N-methyl-D-aspartate receptor-mediated white matter damage.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Aspartic Acid; Brain; Calcium; Di | 2014 |
Role of energy metabolic deficits and oxidative stress in excitotoxic spinal motor neuron degeneration in vivo.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antioxidants; Cell Death; Disease | 2014 |
Differential neuroprotective effects of 5'-deoxy-5'-methylthioadenosine.
Topics: Acute Disease; Adrenergic Antagonists; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Ani | 2014 |
Design, synthesis and pharmacological evaluation of N3 aryl/ heteroaryl substituted 2-((benzyloxy and phenylthio) methyl) 6,7- dimethoxyquinazolin-4(3H)-ones as potential anticonvulsant agents.
Topics: Alanine Transaminase; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvuls | 2014 |
Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; CA1 Region, Hippocampal; Cell Mem | 2014 |
Increased response to glutamate in small diameter dorsal root ganglion neurons after sciatic nerve injury.
Topics: Action Potentials; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Cyclohexylamin | 2014 |
A combination of four active compounds alleviates cerebral ischemia-reperfusion injury in correlation with inhibition of autophagy and modulation of AMPK/mTOR and JNK pathways.
Topics: Adenine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autophagy; Brain; Brain | 2014 |
Contrasting forms of cocaine-evoked plasticity control components of relapse.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Cocaine; Cocaine-Related Disorder | 2014 |
Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Animals, Ne | 2014 |
Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amitriptyline; Animals; Antidepressive Age | 2015 |
Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease.
Topics: Aging; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Pro | 2015 |
Experience-dependent central vision deficits: Neurobiology and visual acuity.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amblyopia; Analysis of Variance; Animals; | 2015 |
Degeneration of spinal motor neurons by chronic AMPA-induced excitotoxicity in vivo and protection by energy substrates.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antioxidants; Ascorbic Acid; Cell | 2015 |
Roles of the NMDA Receptor and EAAC1 Transporter in the Modulation of Extracellular Glutamate by Low and High Affinity AMPA Receptors in the Cerebellum in Vivo: Differential Alteration in Chronic Hyperammonemia.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Cerebellum; Disease Models, Anima | 2015 |
Pathway-Specific Remodeling of Thalamostriatal Synapses in Parkinsonian Mice.
Topics: Adrenergic Agents; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Corpus Striatu | 2016 |
Mitochondrial Dysfunction during the Early Stages of Excitotoxic Spinal Motor Neuron Degeneration in Vivo.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Disease Models, Animal; Excitator | 2016 |
Neuropathological characterization of spinal motor neuron degeneration processes induced by acute and chronic excitotoxic stimulus in vivo.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Apoptosis; Astrocytes; Caspase 3; | 2016 |
Potentiation of synaptic transmission in Rat anterior cingulate cortex by chronic itch.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Behavior, Animal; Chronic Disease | 2016 |
Synaptic plasticity and spatial working memory are impaired in the CD mouse model of Williams-Beuren syndrome.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Brain-Derived Neurotrophic Factor | 2016 |
Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Cerebral Cortex; | 2008 |
Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors participate in the analgesic but not hypnotic effects of emulsified halogenated anaesthetics.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analgesics; Anesthetics, Inhalation; Anima | 2008 |
Chronic intermittent hypoxia impairs heart rate responses to AMPA and NMDA and induces loss of glutamate receptor neurons in nucleus ambiguous of F344 rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Baroreflex; Blood Pressure; Brain | 2009 |
Control of motoneuron survival by angiogenin.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amyotrophic Lateral Sclerosis; Androstadie | 2008 |
Activation of somatostatin receptor (sst 5) protects the rat retina from AMPA-induced neurotoxicity.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amides; Animals; Cell Death; Choline O-Ace | 2010 |
Pattern of injury with a graded excitotoxic insult and ensuing chronic medial septal damage in the rat brain.
Topics: Acetylcholine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Astrocytes; Atroph | 2009 |
The analgesic action of topical diclofenac may be mediated through peripheral NMDA receptor antagonism.
Topics: 2-Amino-5-phosphonovalerate; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Anesthetics, | 2009 |
An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Arachidonic Acids; Astrocytes; Ca | 2010 |
Dysmyelinated axons in shiverer mice are highly vulnerable to alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor-mediated toxicity.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Biomarkers; Brain; Disease Models | 2010 |
Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; alpha-Methyltyrosine; Animals; Biophysics; | 2010 |
Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Animals, Ne | 2010 |
Lateral paracapsular GABAergic synapses in the basolateral amygdala contribute to the anxiolytic effects of beta 3 adrenoceptor activation.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepro | 2010 |
In vivo seizure induction and affinity studies of domoic acid and isodomoic acids-D, -E and -F.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Binding, Co | 2010 |
VEGF protects spinal motor neurons against chronic excitotoxic degeneration in vivo by activation of PI3-K pathway and inhibition of p38MAPK.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Choline O-A | 2010 |
Effects of neonatal inflammation on descending modulation from the rostroventromedial medulla.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Animals, Ne | 2010 |
Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Dyskinesia Agents; Corpus St | 2011 |
Time-domain features of epileptic spikes as potential bio-markers of the epileptogenesis process.
Topics: Action Potentials; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Biomarkers; Co | 2010 |
Inflammation alters trafficking of extrasynaptic AMPA receptors in tonically firing lamina II neurons of the rat spinal dorsal horn.
Topics: Action Potentials; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Biotinylation; | 2011 |
Neonatal tissue damage facilitates nociceptive synaptic input to the developing superficial dorsal horn via NGF-dependent mechanisms.
Topics: Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Animals, Newborn; Ca | 2011 |
Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET.
Topics: Acetamides; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Aminopyridines; Animals; Corpu | 2011 |
Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Brain-Deriv | 2012 |
Reduced effect of stimulation of AMPA receptors on cerebral O₂ consumption in a rat model of autism.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autistic Disorder; Cerebral Corte | 2012 |
Deficits in morphofunctional maturation of hippocampal mossy fiber synapses in a mouse model of intellectual disability.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Animals, Outbred Strains; Disease | 2012 |
Changes in AMPA receptor binding in an animal model of inborn paroxysmal dystonia.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autoradiography; Binding, Competi | 2002 |
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 2003 |
Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Benzodiazepines; | 2003 |
An electrophysiological model of spinal transmission deficits in mouse experimental autoimmune encephalomyelitis.
Topics: Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Disease Models, Anim | 2004 |
Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate receptors mediate development, but not maintenance, of secondary allodynia evoked by first-degree burn in the rat.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Anim | 2004 |
Inhibition of calpains, by treatment with leupeptin, improves motoneuron survival and muscle function in models of motoneuron degeneration.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Animals, Newborn; Calpain; Cell C | 2004 |
Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration.
Topics: Activating Transcription Factor 1; Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic | 2004 |
Neuronal pentraxin 1: a novel mediator of hypoxic-ischemic injury in neonatal brain.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Animals, Newborn; Apoptosis; Brai | 2004 |
Peripheral vestibular disorder induced by (+/-)-alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA).
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Anim | 2004 |
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amino Acids; Analgesics; Animals; Biologic | 2005 |
Recurrent mossy fibers establish aberrant kainate receptor-operated synapses on granule cells from epileptic rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Disease Models, Animal; Electric | 2005 |
Activated PKA and PKC, but not CaMKIIalpha, are required for AMPA/Kainate-mediated pain behavior in the thermal stimulus model.
Topics: 2-Amino-5-phosphonovalerate; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Area | 2005 |
Evaluation of interaction between intrathecal adenosine and MK801 or NBQX in a rat formalin pain model.
Topics: Adenosine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Disease Models, Animal | 2005 |
Remodelling of spinal nociceptive mechanisms in an animal model of monoarthritis.
Topics: Action Potentials; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Ankle; Arthrit | 2005 |
Neurodegenerative actions of interleukin-1 in the rat brain are mediated through increases in seizure activity.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Anticonvuls | 2006 |
Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Barium; Benzothiadiazines; Cerebr | 2006 |
NMDA-NR1 and AMPA-GluR4 receptor subunit immunoreactivities in the absence epileptic WAG/Rij rat.
Topics: Aging; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anterior Thalamic Nuclei; | 2006 |
Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors.
Topics: Action Potentials; Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer | 2006 |
New role for spinal Stargazin in alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-mediated pain sensitization after inflammation.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Anal | 2006 |
Amyotrophic lateral sclerosis 2-deficiency leads to neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA receptor trafficking.
Topics: Adaptor Proteins, Signal Transducing; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amyo | 2006 |
Post-pubertal disruption of medial prefrontal cortical dopamine-glutamate interactions in a developmental animal model of schizophrenia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazo | 2007 |
Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal models.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Benzodiazepines; | 2007 |
Spinal alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors may mediate the analgesic effects of emulsified halogenated anaesthetics.
Topics: Acetic Acid; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analgesics; Anesthetics, Inha | 2007 |
Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Dentate Gyrus; D | 2008 |
Glutamate-mediated excitotoxic death of cultured striatal neurons is mediated by non-NMDA receptors.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Basal Ganglia; Cell Death; Cells, | 1995 |
Spinal mediators of hyperalgesia.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Arachidonic Acid; Arginine; Calci | 1994 |
Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice.
Topics: Acoustic Stimulation; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvuls | 1994 |
Synaptic regeneration and functional recovery after excitotoxic injury in the guinea pig cochlea.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Cochlea; Disease Models, Animal; | 1995 |
AMPA antagonist LY293558 does not affect the severity of hypoxic-ischemic injury in newborn pigs.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Animals, Newborn; Blood Pressure; | 1995 |
Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models.
Topics: 4-Aminopyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Age | 1993 |
LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Disease Models, | 1998 |
N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amino Acids; Animals; Disease Models, Anim | 1999 |
Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicity.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Astrocytes; Cell Culture Techniqu | 2000 |
New non competitive AMPA antagonists.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Anticonvulsa | 2000 |
The N-methyl-D-aspartate antagonistic and opioid components of d-methadone antinociception in the rat spinal cord.
Topics: Action Potentials; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analgesia; Analgesics, | 2000 |
Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Brain; Cell Memb | 2000 |
Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Combinatorial Ch | 2001 |
NMDA receptor function in mouse models of Huntington disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Behavior, Animal; Calcium Channel | 2001 |
Neuroscientists begin to piece together more parts of Huntington's disease puzzle.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Biomarkers; Brain Chemistry; Dise | 1992 |
Chronic quinolinic acid lesions in rats closely resemble Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Atrophy; Biogenic Amines; Cerebra | 1991 |
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 1991 |